377 results about "Low Grade Malignant Neoplasm" patented technology

The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.

The invention provides novel compositions, methods and uses, for the diagnosis, prognosis, prediction, prevention and aid in treatment of malignant neoplasia such as breast cancer, ovarian cancer, gastric cancer, colon cancer, esophageal cancer, mesenchymal cancer, bladder cancer or non-small cell lung cancer. Genes that are chromosomally amplified in breast tissue of breast cancer patients are disclosed. Further disclosed are chromosomally amplified genes and non-amplified genes that correlate to Taxane resistance, Taxane benefit or adverse Taxane reaction, which can be used as an aid to make therapy dicisions.

The invention discloses a beta-carboline ruthenium compound. The molecular formula of the beta-carboline ruthenium compound is [Ru (N^N) 2 (Nh) XClY] (A^A)z, wherein N^N is selected from bpy or phen; A^A is selected from PF6 or SO3CF3; X is equal to 1 or 2, Y is equal to 2-X, and Z is equal to 1 or 2; or the molecular formula of the beta-carboline ruthenium compound is [Ru (N^N) 2 (1-Py-betaC)] (PF^)2, wherein N^N is selected from bpy, phen or DIP. On a molecular mechanism, the invention proves that the beta-carboline ruthenium compound can be used for treating cancers and has a better effectthan the effects of that of the traditional metal compound cisplatin with wide application and ruthenium compounds NAMI-A in clinical tests; . Thethe beta-carboline ruthenium compound for treating the cancers as an autophagic cell inducer fills the blank of the prior art and develops a new line for developing a new generation of high-efficiency medicaments for treating malignant tumors.

The invention discloses a gold nanorods based drug carrier. The carrier is characterized in that: gold nanorods is wrapped with a polyanion film layer, a polycation film layer and an hTERT gene antisense oligonucleotide layer from inside to outside. The gold nanorods based drug carrier is prepared by the layer-by-layer self-assembly principle by utilizing the electrostatic force among radicals, and can be used for preparing inhibitors for malignant tumor cell telomerase. The invention causes hTERT gene antisense oligonucleotide to be loaded on the gold nanorods for the first time to solve the problem of low transfection rate occurred in naked antisense oligonucleotide. The prepared gold nanorods based drug carrier does not only has the advantages of high transfection rate, strong targeting property, obvious effect of inhibiting the activity of the malignant tumor cell telomerase, and the like, but also has the advantages of safety and innocuity, which opens up a new way for the application of the gold nanorods in the biomedicine field; in addition, the invention has the advantages of simple operation for the preparation technology and low cost, and is suitable for scale production.

A method of detecting and diagnosing cancers characterized by the presence of at least one nodule/neoplasm from an imaging scan is presented. To detect nodules in an imaging scan, a 3D CNN using a single feed forward pass of a single network is used. After detection, risk stratification is performed using a supervised or an unsupervised deep learning method to assist in characterizing the detected nodule/neoplasm as benign or malignant. The supervised learning method relies on a 3D CNN used with transfer learning and a graph regularized sparse MTL to determine malignancy. The unsupervised learning method uses clustering to generate labels after which label proportions are used with a novel algorithm to classify malignancy. The method assists radiologists in improving detection rates of lung nodules to facilitate early detection and minimizing errors in diagnosis.

The invention relates to a polypeptide with tumor-targeting performance and a preparation method. The structure of the aminophenol sequence of the polypeptide is CASPSGALRSC or CFPVPGHDLVC or CFSVPGHDIVC or CTPMSLSLSEC or CYTYPLGWHIC. The pC89 phage peptide library expressing protein polypeptides with different sequences of 10⁸ and human breast cancer cell lines MDA-MB-231 are repetitively cocultured for a few times; filtration can penetrate cell membrane to enter into the phages expressing specific polypeptide in cytolymph and / or karyon, and phages are amplified in vitro in order to carry out DNA sequencing and deduce an exogenous amino acid sequence inserted in the phages; the filtered specific polypeptide phages, other human tumor cells and normal cells are cocultured in vitro, and the tumor cell specificity of the polypeptide phages is tested; according to the testing results of polypeptide sequence and cell specificity, the polypeptide with tumor targeting is artifically synthesized. The invention as a specificity carrier of the mammary cancer-targeting genetic therapy has potential clinic application value. The invention also provides a strong technical support for the filtration of affinity specificity polypeptide of other types of malignant tumor cell strains. Moreover, the polypeptide only contains nine to eleven amino acid residues, so the polypeptide can be easily synthesized, the change of spacial position is relatively less, the quality control of the polypeptide is easy, and use is convenient.

The invention discloses a simple method for detecting HLA-G and antibody thereof by gold-labeled immunoassay. The invention uses the monoclonal antibody of HLA-G and an HLA-G antigen fragment and/or HLA-G for successfully developing a gold-labeled immunity percolation analysis kit, and a gold-labeled immunochromatography sandwich method and competition method kit, which are used for the public to easily, rapidly and cheaply self-check and self-test the HLA-G in body fluid such as blood, saliva, urine, and the like so as to diagnose the early malignant tumor. In order to diagnose the earlier malignant tumor, a kit for detecting the HLA-G antibody by a gold-labeled immunochromatography indirect method is also developed and used for diagnosing the earlier malignant tumor. The kits are all called as 'broad-spectrum tumor diagnostic kit'. The invention aims at developing an easy, rapid and cheap 'broad-spectrum tumor diagnostic kit' for the self-check and self-test of the public so as to realize primary tumor screening and achieve the goal of finding and curing the tumor early, save the lives of the tumor patients, and reduce the tumor mortality.

The present invention relates to a medicine for curing malignant tumor and its preparation method. It is made of asparagus tuber, Buddha's hand fruit, American ginseng, acanthopanax obovatus, hippophae rhmnoides fruit, Chinese gooseberry root, venom and bolbostemma tuber as raw material through the processes of removing dust and cleaning, decocting, alcohol precipitation extraction and alcohol impregnating extraction. Said medicine has no toxic side effect, has strong action of resisting tumor and raising immunity of body, and can possess synergistic action and attenuation when it is matched with radiotherapy and chemical medicine therapy to cure malignant tumor, and can obtain good therapeutic effect.

The present invention provides: an antibody or a antibody fragment thereof, which can bind to A33, which specifically attacks A33-expressing tumor cells with the use of ADCC and CDC based on the immune system, and for which no HAHA is produced; and a preventive or therapeutic agent for various malignant tumors including solid tumors that are currently treated with difficulty, which contains the antibody or an antibody fragment thereof. Specifically, the antibody or a functional fragment thereof is capable of binding to A33 and is produced by a hybridoma M10 (accession No. FERM BP-10107), M96 (accession No. FERM BP-10108), M165 (accession No. FERM BP-10106), N26 (accession No. FERM BP-10109), Q47 (accession No. FERM BP-10104), Q54 (accession No. FERM BP-10105), or R5 (accession No. FERM BP-10107). The preventive or therapeutic agent for tumors contains the antibody or a functional fragment thereof.

The invention belongs to the technical field of drugs for resisting malignant tumor and provides nitrogen-containing heterocyclic thienopyridine compounds with the structure shown as a general formula I and salts thereof, wherein R1 is hydrogen, and C1-C4 are alkanoyloxy substituted by alkyl; and R2 is nitrogen-containing six-membered heterocycle, i.e. benzoazo six-membered heterocycle. The invention further relates to a method for preparing the compounds, and also discloses drug compositions taking the compounds or the salts thereof as the active effective components and application thereof as drugs for resisting malignant tumor.

The invention belongs to the technical field of medicine, and relates to pegylated celastrol and a preparation method and application thereof. The pegylated celastrol has a structure shown as a general formula in the specifications. The invention also provides application of the pegylated celastrol and methoxy amino polyethylene glycol 10kDa mono-modified celastrol (mPEG10k-NHCO-celastrol) to preparation of medicines for treating various malignant tumors such as prostatic cancer, lung cancer, liver cancer and cervical cancer. Celastrol is subjected to chemical structural modification by PEG, so that the problem that the celastrol has low solubility can be solved; and an injection can be prepared after the celastrol is modified by the PEG, so that the elimination half life of the celastrol can be prolonged through in-vivo injection, the toxic and side effects of the celastrol are reduced, and the administration frequency of a patient is reduced.

The invention discloses a [<18>F] AlF marked positron emission tomography (PET) polypeptide probe and a preparation method thereof. The probe comprises TMTP1 polypeptide and NOTA, which are connected together, and the structural formulae of the TMTP1 polypeptide and the NOTA are shown in the description. According to the [<18>F] AlF marked positron emission tomography (PET) polypeptide probe and the preparation method thereof, a glycine is added to the TMTP1, and a G-TMTP1 polypeptide is designed, so that the polypeptide does not influence the biological activity after being radioactively marked; furthermore, 18F is taken as a radionuclide, and the G-TMTP1 polypeptide is marked by utilizing a [<18>F] AlF-NOTA method, so that the obtained [<18>F] AlF-marked PET polypeptide probe has excellent pharmacokinetics properties, the background cleaning rate is high, the liver uptake rate is low, in-vivo stability is good, the uptake rate of tumor site is high, highly metastatic tumor can be diagnosed specifically, and the polypeptide probe can be applied to diagnosis or therapeutic evaluation of highly metastatic malignant tumor.

The invention relates to a novel photosensitizer monomer completely soluble in water. Chlorophyll a is taken as a raw material for preparing pheophorbide a, 3-devinyl-3-(1'- hexahydro)ethyl-methyl pheophorbide-a is directly synthesized from pheophorbide a, and a water-soluble salt shown as the structural formula is obtained by processing with an alkali metal hydroxide. In the structural formula, R1, R2 and R3 are H or M, R1, R2 and R3 are not H simultaneously, and M is selected from Na, K or NH4<+>. The above water-soluble salts do not change the large ring structure with photosensitivity, are convenient to apply because of good water solubility, are applicable to prepare medicines for treating or diagnosing malignant tumor (especially superficial malignant tumor in all lumens), precancerous lesions and benign lesion during photodynamic therapy.

The invention provides a traditional Chinese medicine plaster for treating malignant tumors, which is prepared from the following raw materials by weight portion: 80-130 portions of euphorbia pekinensis, 80-130 portions of euphorbia kansui, 80-130 portions of lilac daphne flower bud, 80-130 portions of rhizoma sparganii, 80-130 portions of rhizoma zedoariae, 60-100 portions of frankincense, 60-100 portions of golden cypress, 60-100 portions of rhizoma coptidis, 60-100 portions of rhubarb, 60-100 portions of myrrh, 40-70 portions of nux vomica, 40-70 portions of Chinese gall, 40-70 portions of pillis ophidiae, 40-70 portions of angelica, 40-70 portions of liquorice, 40-70 portions of dried rhizome of rehmannia, 40-70 portions of radix scrophulariae, 40-70 portions of radices trichosanthis, 40-70 portions of fiveleaf akebia fruit, 35-55 portions of centipede, 35-55 portions of scorpio, 35-55 portions of pseudo-ginseng and 35-55 portions of senso. The invention also provides a preparation method of the traditional Chinese medicine plaster. The traditional Chinese medicine plaster is used for treating various malignant tumors, is a preferred plaster for patients with end-stage tumors, i.e. hydrothorax, ascites, jaundice, and the like and has the advantages of innocuity, high safety, low cost, convenient preparation, and the like.

The invention discloses a trinuclear platinum complex (ZD028) capable of inhibiting the telomerase activity with high efficiency, a preparation method and an application of the trinuclear platinum as an antitumor drug. The trinuclear platinum complex can specifically inhibit the telomerase activity of the cancer cell, destroy a telomere maintenance mechanism which is pivotal to the cancer cell, accelerate the shortening of the telomere of the cancer cell, induce the aging of the cancer cell, and lead to death of the cancer cell to reach a purpose for treating malignant tumor, and the toxicity on normal cell is low. The conventional antitumor drug comprises doxorubicin, cisplatin and paclitaxel but not the limitation. Compared with the conventional antitumor drugs, the trinuclear platinum complex (ZD028) reduces the toxic and side effect on other organs or systems due to low toxicity on normal cells. The preparation method has the advantages of simple and easy operation and low cost, can be competed in a common chemical laboratory, and has no environmental pollution during the production process, thereby the trinuclear platinum complex (ZD028) can be used as a novel latent antitumor drug.

The invention discloses a supermolecular assembly for targeted conduction of anticancer taxol prodrug. The supermolecular assembly is a binary supermolecular assembly which is synthesized from full-methylated cyclodextrin modified hyaluronic acid and porphyrin modified taxol prodrug, the binary supermolecular assembly is formed into supermolecular nano particles which take hydrophilic hyaluronic acid as shells and hydrophobic porphyrin modified taxol prodrug as kernels based on the strong non-covalent interaction of full-methylated cyclodextrin and porphyrin and the amphiphilic action of molecules, and the particle size of the nano particles is 30-40nm. The supermolecular assembly has the advantages that the supermolecular assembly is simple in synthesis route, low in production cost, relatively high in yield and applicable to amplified synthesis and practical production and application; due to endocytosis which takes an overexpressed hyaluronic acid receptor on the surface of a malignant cell as a medium, the supermolecular assembly (HATXP) is introduced into cancer cells in a targeted manner, protection on normal cells and targeted selective killing of cancer cells are achieved, the anticancer activity is remarkable, and the toxic and side effects are remarkably reduced.